Clas Lindbergson

Angel investor network formed by seasoned entrepreneurs investing smart money in life science.

Brighter - A human innovation company. Website: https://brighter.se/ Brighter addresses common public health challenges through a group of innovation companies. By introducing groundbreaking technology and innovative services, we aim to improve health outcomes and wellbeing amongst the global population and facilitate increased efficiency throughout the healthcare system. Currently the group has offices in Stockholm, Dubai and Jakarta.. Brighter's shares are listed on Nasdaq First North Growth Market/BRIG. Stock trading: www.bloomberg.com/quote/BRIG:SS

FrostPharma is an entrepreneurial Swedish Specialty Pharma company specializing in the commercialization of value-adding medicines. FrostPharma signed its first product distribution agreement in 2017, and since then 35 products have been added to the therapy agnostic portfolio through a strong agreement deal-flow, as well as through the development of proprietary products. The company has an established specialty pharma platform across the Nordics, and now actively plan to expand to additional EU countries. The FrostPharma portfolio of products are primarily oriented toward hospital use, and hospital initiation. FrostPharma has also developed a separate division offering sustainable solutions to petroleum based plastics across the Healthcare sector. Please contact us at: info@frostpharma.com

Angel investor network formed by seasoned entrepreneurs investing smart money in life science.

Brighter - A human innovation company. Website: https://brighter.se/ Brighter addresses common public health challenges through a group of innovation companies. By introducing groundbreaking technology and innovative services, we aim to improve health outcomes and wellbeing amongst the global population and facilitate increased efficiency throughout the healthcare system. Currently the group has offices in Stockholm, Dubai and Jakarta.. Brighter's shares are listed on Nasdaq First North Growth Market/BRIG. Stock trading: www.bloomberg.com/quote/BRIG:SS

FrostPharma is an entrepreneurial Swedish Specialty Pharma company specializing in the commercialization of value-adding medicines. FrostPharma signed its first product distribution agreement in 2017, and since then 35 products have been added to the therapy agnostic portfolio through a strong agreement deal-flow, as well as through the development of proprietary products. The company has an established specialty pharma platform across the Nordics, and now actively plan to expand to additional EU countries. The FrostPharma portfolio of products are primarily oriented toward hospital use, and hospital initiation. FrostPharma has also developed a separate division offering sustainable solutions to petroleum based plastics across the Healthcare sector. Please contact us at: info@frostpharma.com

At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US. Comments and posts by users on this site are not created or controlled by Eisai Inc. and Eisai is not responsible for such content.